Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE

This study has been completed.
Information provided by (Responsible Party):
Sanofi Pasteur MSD Identifier:
First received: March 2, 2012
Last updated: April 10, 2013
Last verified: April 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)